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Abstract
Although the Human Papillomavirus (HPV) vaccine has been approved and
recommended by the FDA and other vaccine experts (ACIP, AAP, AAFP, and ACOG) for over a
decade, the national uptake rate of the HPV vaccine has remained below the Healthy People
2020 goal of 80% (OFPHP, 2018). In 2016, the clinic’s completion rate for the HPV series was
only 27.7% among adolescents 11- to 13-years-old, which was not only below national targets,
but also below the organization’s completion rate goal of 30.4%. Last year, in 2017, the
Burlingame pediatric primary care clinic implemented the HPV Vaccination Improvement
Project through the Pediatric Service Line and was able to increase their completion rates up to
31.1%, which surpassed the previous year’s organizational goal. For this year, the most recent
completion rate was 16.9% as of April and our current completion rate goal for this year is
34.4%.
This change project aims to increase the rates of HPV vaccine uptake in the pediatric
primary care clinic through patient outreach and reminder/recall telephone calls and mailed
letters. The quality improvement project was initially based on the 4 Pillars of Practice
Transformation program, however, due to the limitations of this project, we have chosen to focus
on just one strategy/intervention to improve HPV vaccine rates in the clinic.
The project is planned to start July 9, 2018 and go until July 30, 2018. We will measure a
combination of process, outcome and balancing measures, including HPV initiation and
completion rates, number of HPV vaccines given and appointments scheduled as a result of
patient outreach calls. Additionally, we will track “used opportunities to vaccinate”, missed
opportunities to vaccinate and simultaneous vaccines given.
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As a result of the outreach calls, we were able to schedule a total of 40 appointments. Out
of the patients who came in for their appointments, 11 patients completed the HPV series and
two patients initiated the HPV series; this led to an improvement of about 2%, which was less
than our goal of 5-10% improvement. However, if all 40 patients who were scheduled as a result
of the outreach calls came in to their appointments and received an HPV vaccine, then that
would translate to an improvement rate of 7% which would meet our goal.
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Improving Rates of HPV Immunization in the Pediatric Primary Care Setting
Problem Description
The Human Papillomavirus (HPV) is the most commonly sexually transmitted infection
(STI); it is estimated that about 79 million Americans (in their late teens and early 20s) are
infected with HPV (Centers for Disease Prevention and Control [CDC], 2017). Another 14
million people become infected each year (CDC, 2017). In some cases, HPV resolves on its own
and does not cause any long term health consequences. However, certain strains of HPV can
cause genital warts or cancer. At any given time, it is estimated that about one in every 100
sexually active adults in the United States (U.S.) has genital warts caused by HPV (CDC, 2017).
HPV can also cause cervical cancer, as well as other cancers, including: cancer of the vulva,
penis, anus, and oropharynx. Approximately 12,000 women in the U.S. will be diagnosed with
cervical cancer every year, and 4,000 women will die from it (CDC, 2017).
Although people can be tested for HPV, there is no way to determine which individuals
will develop cancer or other HPV-related conditions (CDC, 2016). Unfortunately, the type of
cancers caused by HPV do not usually show any obvious symptoms until it is at advanced stages,
and by that point they are very serious and difficult to treat. Regular screening for cervical cancer
can detect the earliest signs of this disease, but there aren’t any other diagnostic tools available to
detect the other types of cancers caused by HPV. Consequently, it is necessary and (more
effective) to prevent HPV infection through vaccination. HPV vaccines have been available and
recommended by the U.S. Advisory Committee on Immunization Practices (ACIP) for
adolescent girls since 2006, and for adolescent boys since 2011 (National Cancer Institute [NCI],
2013).
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Two years ago, in 2016, the CDC approved a reduction in the number of HPV doses
required for adequate protection to two doses for adolescents 15 years of age and younger,
reducing the amount office visits needed to complete the series (CDC, 2018a; California
Emerging Infections Program, n.d.). Although the benefits of HPV vaccines are significant, and
it is now easier to complete the HPV series, the uptake of this vaccine remains way below the
target level.
The pediatric primary care clinic in Burlingame started tracking HPV series initiation and
completion rates in 2016. In 2016, there were 394 pediatric patients (between the ages of 11-13
years old) who were eligible to start the HPV vaccination series; 109 of those patients completed
the vaccination series, 102 patients started, but did not complete the series, and 183 patients did
not start the series. This led to a completion rate of 27.7%, which was below the organization’s
completion rate goal of 30.4%. This shortcoming led to the development and implementation of
an HPV Vaccination Improvement Project on behalf of the Pediatric Service Line.
In an attempt to increase HPV vaccination rates, several interventions, including outreach
calls, an HPV Tool Kit, and an HPV workflow, were developed and implemented in 17 different
pediatric clinics throughout the organization. As a result of the HPV Vaccination Improvement
Project, the Burlingame pediatric clinic was able to increase the rates of HPV vaccination to
meet and surpass the organization’s goals the following year. In 2017, there were 534 pediatric
patients eligible to start the series; 166 of those patients completed the vaccination series, 155
patients started, but did not complete the series, and 213 patients did not start the series. This led
to a completion rate of 31.1%, which met and surpassed the 2017 completion rate goal of 30.4%.
The most recent data is from April 2018, which shows that there were 545 eligible
patients this year; so far only 92 patients have completed the series, 138 patients have started, but

IMPROVING RATES OF HPV VACCINATION

6

not yet completed the series, and 315 patients have not started the series. The completion rate
goal for 2018 has increased to 34.4%, however, as of April 2018 the actual completion rate was
16.9%, almost halfway to the annual completion goal. Although it is important to acknowledge
the efforts and the improvement that has already been accomplished by the Pediatric Service
Line’s HPV Vaccination Improvement Project, it is also important to recognize that there is
much more progress to be made to increase the rates of HPV vaccination to meet the
recommendations of national experts, such as those established by Healthy People 2020.
Although the initial HPV Vaccination Improvement project was able to increase the rates of
HPV vaccination enough to meet and surpass the organization’s goal, it seems that the initial
progress has not been sustainable.
The Office of Disease Prevention and Health Promotion’s (OFPHP) (2018) Healthy
People 2020, Objective IID-11 addresses the importance of increasing routine vaccination
coverage levels for adolescents. More specifically, objectives IID-11.4 and IID-11.5 suggest
increasing the coverage level of the HPV series for both females and males within the ages of 13
to 15 years. In 2012, 28.1% of females, and only 6.9% of males, aged 13-15 years old, had
completed the recommended HPV vaccine series (OFPHP, 2018). However, the target
percentage, as proposed by Healthy People 2020, has been 80% for both males and females since
2010. Although the objectives for Healthy People 2020 were written before the dose change in
2016, it is clear that the clinic’s target completion rate for the HPV series should be much higher
than what is has been. It is important for the clinic’s completion rate goal (and actual completion
rate) to be more closely aligned with the Healthy People 2020 target of 80%, so that we can
ensure that more of our patients can benefit from primary prevention through vaccination.
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The Burlingame pediatric primary care office’s HPV vaccination initiation and
completion rates are not only below the target rates of national recommendations, but they also
remain below actual national and state rates. It is important to note that most national- and statelevel HPV vaccination surveillance data is limited to adolescents between 13- and 17-year-olds;
however, we will use this information for comparison. In 2016, 43.4% of adolescents (49.4% of
females and 37.5% of males) had completed the HPV series (when the updated HPV
recommendations were applied retrospectively) (Walker et al., 2017). Additionally, HPV vaccine
initiation rates (adolescents vaccinated with at least one dose or more of HPV) varied from
50.4% in rural areas, up to 65.9% in metropolitan areas (Walker et al., 2017). In 2012, 65.0% of
adolescent females (13-17 years old) in California initiated the HPV vaccine series and 35.8%
completed the series (Cook et al., 2014). In the same year, 29.4% of adolescent males of the
same age initiated the HPV vaccine series and 11.7% completed the series (Cook et al., 2014).
Increasing the rates of HPV vaccination series initiation and completion among the
adolescent patients of the Burlingame pediatric primary care clinic is important because the HPV
vaccine is most effective when given at a younger age, before the initiation of sexual activity and
potential exposure to HPV (CDC, 2018).
Available Knowledge
There has been a substantial amount of research on the barriers and facilitators to HPV
vaccine uptake, as well as on specific interventions and strategies to improve the rates of
adolescent vaccines, including the HPV vaccine series initiation and completion, among eligible
patients. For this literature review, it is important to focus on past studies that focused on similar
interventions as the ones proposed for this small test of change project (See Appendix A for
evaluation table).
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A population, intervention, comparison and outcome (PICO) question was developed to
conduct a literature review to support the project: Can the implementation of outreach
calls/reminders for adolescent patients who have not initiated or completed the HPV vaccine
series increase/improve HPV vaccination rates compared to standard of care (no treatment)? The
PICO question was used to conduct an electronic search in the Cochrane Database of Systematic
Reviews, Pub Med, and CINAHL Complete databases. The most appropriate and useful finding
was a systematic review from the Cochrane Library on patient reminder and recall interventions
to improve immunization rates (Jacobson Vann, Jacobson, Coyne-Beasley, Asafu-Adjei, &
Szilagyim, 2018). The systematic review included a total of 75 studies, which included child,
adolescent, and adult patients within outpatient, community-based, primary care, and other
settings in 10 different countries. Due to the limitations of this project and time, it was not
possible to review every study included in the systematic review. Twelve studies examined the
effect of patient reminder or recall on receipt of adolescent immunizations; of these, only six
were applicable to the intended project and will be further discussed in this section. Another,
fourteen studies examined the effect of immunization reminder telephone calls (person-toperson) on receipt of immunizations; only three of these studies could be applied to the intended
project, but they were not included in the literature review because they did not add any new or
useful information. The selected articles were evaluated using the Johns Hopkins EvidenceBased Practice (JHEBP) research evidence appraisal tool (See Appendix B).
Brigham, Woods, Steltz, Sandora, and Blood (2015) conducted a randomized control trial
(RCT) to determine if adolescent vaccination rates could be improved by contacting parents only
or both parents and patients. The RCT included three study arms: in the control group (control),
no specific outreach was initiated; in the first intervention arm (parent only), the parent or
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guardian was called to inform of overdue vaccination; in the second intervention arm
(parent/adol), both the parent/guardian and the patient were called to inform of overdue
vaccination. Participants were identified from the Adolescent Medicine Practice at Boston’s
Children’s Hospital by searching the EHR for patients with a billing code for a physical exam
within the last three years; and included adolescents between 13- and 17-years-old that met the
following criteria: those who had not received meningococcal vaccine (MCV4), had not received
Tdap in five years, or had only received one varicella vaccine and did not have a history of
varicella disease or chicken pox. Out of a total of 1099 individuals, 424 met the inclusion
criteria. Subjects were followed for a year after the interventions; their immunization records
were reviewed for any new vaccines at four weeks and one year after randomization (Brigham,
Woods, Steltz, Sandora, & Blood, 2015).
Brigham et al.’s (2015) study found that at four weeks after the intervention, there was a
nonsignificant trend of increased immunization rates in both intervention arms (14.4% in parent
only, and 14.5% in parent/adol), when compared to the control group (7.1%). The study found
that the trend of increased immunization did not persist one year after the intervention (35.5% in
the control, 41.4% in parent only, and 38.4% in parent/adol). Although the intervention showed
improvement in vaccination in the short term, it was not able to sustain that improvement in the
long term (Brigham et al., 2015). Although the study did not include the HPV vaccine as an
adolescent vaccine, the findings on the efficacy of the intervention (telephone calls) can still be
applied to the project. The evidence presented was a Level I and good quality (See Appendix A).
Chao, Preciado, Slezak, and Lanfang (2014) conducted a randomized intervention study
to determine if quarterly reminder letters would improve HPV series completion rates among 9to 26-year-old females. Eighty percent of eligible females at Kaiser Permanente Southern
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California (KPSC) who met the eligibility criteria were randomly selected to be in the
intervention group. The intervention group received a letter reminding patients of the HPV
vaccination schedule, the date of their first dose of HPV, a message to encourage the patient to
return to the clinic to complete the series, and the phone number to call to schedule an
appointment to receive vaccination. Three months after the first mailing, HPV vaccination status
was re-evaluated for each participant; if they had not completed the HPV series, and did not meet
any exclusion criteria, then they were sent another letter (four letters total). The rest of the 20%
of eligible females were randomly assigned to the control group, which received standard of care
and were not mailed any reminder letters.
Chao et al.’s (2014) study found that the (3-dose) completion rate was 56.4% at the end
of 12 months for intervention group, compared to 46.6% in the control group (p< .01). Patients
who had only received one dose of HPV at baseline, 40% of those in the intervention group and
30% of those in the control group were able to complete the HPV series. In contrast, in the same
group, 20% of girls (9-17-years old) and 43% of young women (18-26-years old), did not receive
any additional doses of HPV during the 12-month-long intervention period. This study is
relevant to the project because we will be sending mailed reminders or outreach letters for those
patients that we are not able to contact by phone, so it is important to examine the validity of this
intervention as well. The evidence presented was Level I and good quality (See Appendix A).
Suh et al. (2012) conducted a RCT to determine if a combination of reminder/recall (R/R)
intervention, including auto dialer telephone calls, followed up by a letter reminder, would
increase the receipt of one or more targeted vaccines, as well as receipt of all targeted vaccines
within six months of the intervention, compared to a control group treated with usual care. The
study involved 400 patients, from four private pediatric practices, for a total of 1600 participants.
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Patients were 11- to 18-years-old, who had been seen within the last two years and who had not
received one or more of the following vaccines: Tdap, MCV4, or first HPV for female patients
only. A secondary outcome of the study was to determine the completion of the following
vaccine series at 12 months after the intervention: Hepatitis A and B, Varicella, and HPV for
females only.
Suh et al. (2012) found that a significantly higher percentage of patients in the
intervention group received at least one of the targeted vaccines (p<.001) and there was also a
significantly higher percentage of patients in the intervention group that received all targeted
vaccines (p<.001). Overall, there was a significant increase in the intervention group for each
vaccine, but HPV rates still remained lower than the other two targeted vaccines (Tdap and
MCV4). This study also considered the cost of the intervention to improve vaccination rates, and
they completed a cost analysis for the project. The cost analysis showed a positive net revenue
and positive net additional revenue for three of the four practices, although one practice showed
a loss (Suh et al., 2012). This study is relevant to the project because we will be utilizing a
similar combination of outreach methods. The cost benefit analysis is also useful to support the
cost effectiveness of these types of interventions. The evidence presented was Level I and high
quality (See Appendix A).
In another study by Szilagyi et al. (2006), a RCT was conducted to compare the effect of
audiotaped telephone reminders for scheduled or needed immunizations and physical exams with
standard care. The study identified 5,902 adolescents between the ages of 11- and 14-years-old,
however only 3,006 were eligible for randomization. Patients had to have been seen within the
last two years and be due for an annual physical, tetanus booster (Td), or Hepatitis B vaccination.
Participants in the study group were called weekly if there was no response. Szilagyi et al. (2006)
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found that at the end of the study, the intervention group had higher coverage of Hep B when
compared to the control group (62.0% and 57.8%). Although both groups increased rates of Hep
B and Td vaccinations, only the increase in Hep B vaccination was significant. The intervention
was most effective at the beginning of the study, but the positive effects were not persistent.
Although the study is older, and was conducted before the HPV vaccine was approved and
recommended for adolescents, the findings can be useful and applied to other adolescent
vaccines. The study is relevant because the intended project has a short duration, and based on
these findings should lead to improved vaccination rates in the short term. The evidence
presented was Level I and good quality.
Szilagyi et al. (2011) conducted another RCT to determine if this time a tiered
intervention provided by a trained patient immunization navigator to improve adolescent
vaccination rates was more effective than the previous study. Patients were selected from eight
different primary care practices in Rochester. Patients had to be between 11- to 15-years old and
had to have been seen in the office within the last two years; 7,547 adolescents were identified
and randomized into two different groups. The intervention group involved different levels of
outreach, with each subsequent level being more intensive than the last. Patients in the
intervention group were tracked, and then were sent telephone and mailed reminders/recall. If
patients did not respond to those efforts, home visits were made to determine and assess any
other barriers to vaccination. Because home visits took more time and were costlier, this
intervention was only used sparingly. The control group received standard of care; however, all
practices were already sending letter and telephone reminders for scheduled visits, but there were
no active reminders or recall based on vaccination status (Szilagyi et al., 2011).
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The study by Szilagyi et al. (2011) found that immunization rates increased by 12 to 16%
for all three adolescent vaccines (including HPV in females) in the intervention group compared
to the control group. Preventive care visit rates were also higher in the intervention group by 917%. This study was relevant because the intervention was carried out by a trained patient
immunization navigator, as opposed to someone who might not be knowledgeable regarding the
clinical aspects of vaccinations. The evidence presented was Level I and great quality (See
Appendix A).
The final study is another by Szilagyi et al. (2013), where a RCT was conducted to
determine which intervention (mailed reminders or telephone calls) was more effective to
increase vaccination rates compared to standard of care control group. Patients had to not have
had a preventive care visit within the last 14 months and/or be eligible for Tdap, MCV4, or HPV
vaccine; 4,115 patients were selected among 37 primary care offices. Adolescents were
randomized into one of three groups. In the first intervention group, letters were mailed every 10
weeks (max of five reminders in one year), except for HPV where letters were mailed every 10
weeks for the first dose only, and every 5 weeks for the second or third dose of HPV (max of
eight reminders per HPV dose). In the other intervention group, telephone calls were made at the
same frequency that the letters that were sent. The control group received standard care from
each practice; however, some practices already used some sort of telephone or mailed reminders
for scheduled visits and for patients behind on vaccinations (Szilagyi et al., 2013).
The study found that immunization rates for individual vaccines and rates for all vaccines
combined were 4-9% greater in the intervention group compared to the control group (Szilagyi et
al., 2013). There was not much difference in improvement rates between the two interventions,
but the difference between the intervention groups was significant when compared to the control
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compared to the control group. About 13% of patients in the control group received all
vaccinations, but preventative visits actually declined in the control group from 63 to 59%
(Szilagyi et al., 2013). The study is relevant because it supports the proposed intervention, and
the sample size was from many different types of care settings, thus the results can be
generalizable to other practices. The evidence presented in this study was Level I and great
quality (See Appendix A).
A common theme throughout the literature review is the frequency with which
reminder/recall interventions are recommended and encouraged as an effective strategy to
improve vaccination rates among various populations, and experts, such as the Task Force on
Community Preventive Services, have recommended this strategy (Szilagyi et al., 2013).
However, the evidence available to support this intervention has been mixed between negative
and positive outcomes. Many of the studies included in the literature review suggest that
reminder/recall interventions do provide at least some positive effect on vaccination rates
compared to control groups, however, the benefits of this strategy are often limited to the short
term and often blunted due to a lack of accurate contact information (telephone number or
mailing address) for patients.
Rationale
Increasing HPV vaccine rates in our pre-adolescent and adolescent patients has already
been a priority for the primary care clinic for more than two years. Although we have already
seen some improvement in the rates and were able to meet the organization’s goals, our HPV
immunization rates still remain below the national targets. However, it is important to take
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advantage of the current momentum and recent victories, to encourage and support the quality
improvement efforts even further.
Although the HPV Vaccination Improvement Project already attempted to use outreach
calls as an intervention or strategy to improve HPV vaccine uptake, the microsystem assessment
revealed that the last of the outreach calls were done sometime last year. Additionally, the
outreach calls that were done before, were done by a group of patient service representatives
(PSRs) outside of the clinical area. The PSRs were also responsible for making outreach calls to
all of the 17 pediatric clinics, which is a very large undertaking. However, it is unclear whether
the PSRs had any previous training or education with pediatric patients, vaccination schedules
and recommendations. In the study done by Szilagyi et al. (2011), the intervention was carried
out by a trained patient immunization navigator and the results of the intervention were positive.
Although the authors did not make a correlation between the results of the study and the training
or education of the immunization navigator, it would be interesting to investigate if outreach
calls done by clinical (and knowledgeable) pediatric staff will improve the results of the
intervention; this is assuming that the clinical staff would be able to answer any questions and
provide rationales for the HPV vaccine.
Initial inspiration for this project was based on the “4 Pillars of Practice Transformation
Program” (4 Pillars Program), which was found during a previous literature review (Zimmerman
et al., 2017). The 4 Pillars Program is an evidence-based, step-by-step guide used to improve
immunization rates in outpatient settings (University of Pittsburg, 2018). Zimmerman et al.
(2017) conducted a pre-post study using Diffusion of Innovations theory, the 4 Pillars Program,
provider education, and individual coaching of an Immunization Champion for each clinical site.
Each practice was expected to choose and implement strategies from each of the four pillars;
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they were also encouraged to employ as many strategies as possible in an attempt to maximize
effects of the program on vaccination rates. Strategies used by the different practices included:
using every opportunity to vaccinate, developing and implementing standing order protocols for
RNs to vaccinate, reminding patients of subsequent doses, and office wide recommendations
encouraging vaccinations (Zimmerman et al., 2017). Researchers found that primary care
practices who implemented the 4 Pillars Program were able to observe clinically and statistically
significant improvements in HPV vaccine series initiation and completion, as well as
improvements in other adolescent vaccines, including: meningococcal and Tdap vaccines
(Zimmerman et al, 2017).
Although the initial plan was to use the 4 Pillars Program as a guide for the quality
improvement project, due to the limitations and time constraints of the project, the plan was
eventually simplified to focus on just one intervention/strategy to try to improve HPV vaccine
series initiation and completion rates in the pediatric setting. We chose a reminder/recall
intervention, which falls under Pillar 2: Patient Communication Strategies; however, this
intervention is related to other interventions under different pillars (See Appendix C) (University
of Pittsburg, 2018).
Various theories have been used to introduce the 4 Pillars Program in the primary care
setting (Zimmerman et al., 2018). However, since this quality improvement project will be led by
the CNL student, who is in the perfect position to support and reinforce the quality improvement
process, we will use and focus on Lippit’s phases of change theory (See Appendix D) as a guide
and framework to implement the outreach call/reminder/recall intervention in the pediatric
primary care clinic. Lippit’s theory is especially useful for the CNL because it focuses on the
change agent and highlights his or her ability to work together with the interdisciplinary team to
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improve patient outcomes through the application of evidence-based practice. Lippit’s phases of
change theory will be discussed further in the context section of this paper.
Specific Project Aim
The purpose of the quality improvement project is primarily to improve the initiation and
completion rates of the HPV vaccine series in the pediatric clinic. As we review each patient’s
electronic health record and immunization report, we expect to find other vaccines or
preventative visits (annual physicals) that are overdue. In an attempt to improve primary
prevention and reduce missed opportunities, a secondary purpose of the project is to ensure that
patients are up to date with other routine and adolescent vaccines, as well as preventative visits.
Our global aim statement is as follows: We aim to improve the initiation and completion
rates of HPV vaccination in the BG pediatric primary care clinic. The process begins by
identifying patients who are eligible to initiate the HPV vaccine series but have not done so and
patients who have initiated, but not yet completed, the HPV vaccine series. The process ends
with scheduling patients to come in for a physical exam or a care team visit to accept/receive the
HPV vaccine (and any other vaccines that may be overdue). By working on the process, we
expect (1) to increase the HPV initiation and completion rates to meet and surpass the
organizational goals, and (2) to reduce the gap between our completion rate and the national
target rate of 80%(ODPHP, 2018). It is important to work on this now because we have
identified the need to improve (1) our HPV vaccination initiation and completion rates to meet
organizational goals and national targets, (2) there is no standardized process to track and reach
out to patients who are behind on their HPV vaccines, and (3) to reduce missed opportunities to
vaccinate.
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Our specific aim is as follows: We aim to improve the initiation and completion rate of
the HPV vaccine series in the BG pediatric primary care clinic, through outreach calls and
mailed letter reminders of overdue vaccines or physical exams starting July 9th, 2018. We hope to
improve HPV vaccination rates and completion by 5-10% within three weeks, by July 30th, 2018.
Context
As previously discussed, the BG pediatric primary care clinic has already participated in
a previous (and still current) quality improvement project to increase HPV immunization rates
among adolescents who are 11- to 13-years-old. Previous strategies and interventions have been
shown to be effective enough to increase the HPV immunization rates to meet the organizational
goals, but not national targets. It is important for the CNL to take advantage of the momentum
and organizational support that already exists regarding this topic, to promote buy-in and staff
interest and collaboration for the new project. Additionally, success of previous quality
improvement efforts supports a culture of safety within the microsystem, as well as reflects the
staff’s commitment to improving patient care.
Cause and Effect: Fishbone Diagram
As part of the microsystem assessment the team created a fishbone diagram to illustrate
possible causes for low HPV rates in the pediatric primary care clinic (See Appendix E). Some
of the more common barriers to HPV vaccination appear to be related to the patient (and their
parents or guardians). These reasons demonstrate that there is need for more education regarding
the HPV vaccine and vaccine-preventable diseases. Outreach calls that are done by clinical staff
can be useful to provide some of this education to our families as well as clarify any
misunderstandings that they may have that have prevented the patient from receiving the HPV
vaccine in the past.
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Process issues also seem to point to problems scheduling appointments through the call
center. Part of the problem relays back to the issue of education and knowledge of the HPV
vaccine; where the PSR may not be familiar with the HPV vaccine and the recommended
schedules. We have found that many PSRs schedule appointments based on the patient snapshot,
which is sometimes inaccurate, outdated, or does not reflect that the patient is on an alternative
vaccination schedule. Outreach calls by trained and knowledgeable clinical staff would bypass
the need for the parent to navigate through the call center telephone tree, as well as provide more
accurate and patient-centered guidelines for vaccines. Additionally, clinical staff who are local to
the clinic are able to manipulate the NonMD schedule to fit the needs of the patients by
collaborating with providers and other care team members to offer appointments that the PSRs in
the call center may not have access to due to provider blocks.
SWOT Analysis
It was also important to create a SWOT Analysis as part of the microsystem assessment
to discuss the strengths, weaknesses, opportunities and threats for the quality improvement
project (See Appendix F). One of the main findings of the SWOT analysis (which is also
reflected in the cause and effect diagram) is the increased rate of recent staff turnover and
inadequate staffing. Although this is very common and pervasive problem in healthcare, staff
turnover has been unusually high in the BG pediatric primary care clinic to the point where it is
now at a 100% of supportive and direct patient care staff, including medical assistants (MAs) and
LVNs. Consequently, we have had various different float staff from the float pool covering the
clinic and the Non MD schedule, as well as staff from other pediatric clinics floating to the BG
location.
This issue has created many different problems in the clinic, internally and externally. It
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also affects the ability of the CNL to implement a quality improvement project without a
dedicated and consistent staff. Additionally, this issue creates more of a task-oriented staff and
focus, such as a “let’s just get things done” or “let’s just get through the day” type of an attitude
that does not support quality improvement efforts. One way to address this issue, is to create a
“cheat sheet” for the floating staff in regards to common HPV questions, so that new staff is
prepared to answer vaccine questions in a consistent manner. Since there was already a preexisting resource created by the initial HPV Vaccine Improvement project, it was not necessary
to recreate this document again (See Appendix G). Additionally, communication between the
care team (CNL/RN, MA, LVN, MD) becomes even more important and critical for efficient
patient care.
Return on Investment (Cost Analysis)
As with any quality improvement project, it is important to address the economic side of
an intervention and small test of change. The team met to develop and create a business case for
the project because a thorough cost-benefit analysis is important to stakeholders within the
organization. Additionally, the increasing importance of fiscal stewardship within healthcare
affects the stakeholders, as well as the microsystem staff; it would be irresponsible for the staff
to take on a project without being aware of the potential cost and benefit to the organization.
Costs. Expected costs would include the salary rate of the CNL to develop and
implement the project. According to NurseJournal.org (2018), the national median annual wage
for a CNL is $84,000 or about $40.38/hour (assuming a 40-hour work week). For a project that is
expected to take about 220 hours, this would mean a total cost of $8,883.60. The proposed
intervention of outreach calls should not incur extra costs other than time, since we have the
equipment and services in the clinic already (telephone, telephone service). We have access to
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patient demographics (telephone number and address) via the EHR that is already in place, as
well as the ability to send messages through the EHR. Cost of the project may be reduced if other
staff can be recruited to help with outreach calls. According to Salary.com (2018b, 2018a), the
median expected hourly pay for a medical assistant in the US is $16, and the median annual
salary for a clinic receptionist is $34,106 or $16.40/hour; which would reduce the cost for the
project down to about $3520 - $3608.
Other costs to consider would be the cost of the vaccines; if we are able to increase the
rates of HPV vaccination then we would need to order more vaccines and supplies to
accommodate increased demand. According to the CDC (2018), Guardasil-9 (which is the
vaccine we use at the BG clinic) costs $204.87 per dose for private sector; we do not have any
vaccines provided by the Vaccines for Children (VFC) Program. Guardasil-9 comes in a box of
10, translating to a cost of $2,048.70 per box. Since the goal of the project is to increase HPV
initiation and completion rates by 5-10%, this would translate to an additional 28-55 HPV
vaccines, or an additional cost of $5,736.36 - $11,267.85.
Benefits. Benefits to the employer would include the reimbursement for the service of
providing vaccines. According to Sutter (2015) Healthcare Cost Estimator, Human
Papillomavirus (HPV) vaccine, 3 dose total charge is $260, with total patient responsibility being
$234 (for uninsured patients). Additionally, there is an immunization administration with face to
face counseling cost of $65, with total patient responsibility of $45. The total billed charge is
$325, and total patient responsibility is $279. This would translate to a benefit of $7,812 $15,345. A doctor’s office visit for an established patient, nurse visit is charged at $63 and
patient responsibility is $57. A doctor’s office visit for an established patient, moderate level
visit is charged at $220 and patient responsibility is $198. This would mean an additional benefit
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of $1,596 - $3,135 for nurses visits, or $5,544 - $10,890 for physical exam, where patients would
be able to receive vaccines in either type of visit.
Net Benefits. The goal of the project is to increase HPV immunization by 5-10% or 2855 patients. The different variables (how many vaccines are needed for completion per patient
and type of visit appropriate for each patient) make it a little difficult to determine the net
benefits. However, a rough estimate will be based on just one vaccine given per patient during
the project duration. For simplicity purposes and to estimate the lowest (most conservative) net
benefits, this will be calculated using nurse visits as the type of visit for patients to receive
vaccines. Based on these parameters, for each patient, benefits would equal to $336 ($279 +
$57); for a 5-10% increase, benefits would equal $9,408 - $18,480. The net benefit would be
~$524.40 - $9,596.40.
Qualitative Benefits. Qualitative benefits to the patient would include reduced risk of
infection with HPV (and its’ associated cancers) and overall improvement of quality of life. This
would translate to a reduction in the direct and indirect medical costs of the disease and its’
treatment.
Qualitative benefits to the clinic (the employer) would include improvement of HPV
vaccine initiation and completion rates, putting the clinic (and organization) more closely aligned
with national recommendations and targets. Additionally, reduced missed opportunities for
vaccination translate to improved efficiency and patient satisfaction, and reduces the need for
additional visits. Earlier (younger) HPV vaccine series initiation and completion reduces the
amount of vaccines needed to complete the series-- which can be more cost effective for the both
the clinic and the patient.
Lippitt’s phases of change theory revisited
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Lippitt’s phases of change theory was introduced in a previous section, but it is important
to discuss it here as well. Although there are many different change theories available to guide a
change process, it is the responsibility of the change agent to select the most appropriate theory
for the project after considering the culture of the microsystem. Although Lippit’s (1958) theory
is more complicated than Roger’s Diffusion of Innovations theory, it provides the change agent
with a more detailed plan of how to realize change successfully (as cited in Mitchell, 2013).
Furthermore, since Lippit’s theory is based on the four elements of the nursing process, the
process is familiar to all nurses, including the CNL, and provides a good starting point for novice
change agents and clinical leaders (Mitchell, 2013).
Lippit’s theory is applicable to the microsystem now because it focuses on the change
agent, rather than the change itself. It is important that the change agent focus on effective
“communication, feedback on progress, teamwork and motivation” (Mitchell, 2013, p. 36). Since
the clinic is going through a major change in staff, it is especially important for the CNL to take
on the leadership role of the quality improvement project and guide the float staff through the
process. Although teamwork and collaboration is still an important part of the project, the CNL
must be creative and innovative in order to motivate the staff to commit to and participate in the
quality improvement project, especially when they have competing priorities.
In the final stage of Lippitt’s theory, it is important for the change agent to take a step
back at the end of the project, and let the team embrace and integrate the change into the
microsystem; however, it is helpful for the change agent to still be available for support to and
encouragement for the team (Mitchell, 2013). We are hopeful that by the end of the project, we
will have better and more consistent, possibly permanent, staffing of the clinic. At that point it
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will be easier for the CNL to step back and allow the team to embrace and be responsible for a
larger portion of the project, if we determine that it is successful.
Intervention
Through a microsystem assessment and discussion with our pediatric PSR, it was
discovered that there is already a list of patients who are overdue to initiate or to complete the
HPV vaccination series. This report is left over from when the HPV Vaccination Improvement
Project was doing outreach calls last year. The status of this report, and whether it has been
updated and maintained, is unknown. However, since the HPV Vaccination Improvement Project
team is still generating reports to update the HPV initiation and completion rates of each clinic, it
is possible that the list still exists. We have contacted one of the Pediatric Service Line’s
coordinators to request a copy of this list and are waiting to hear back.
If it is possible to obtain the list, then we will initiate outreach calls based on the patients
on the list who belong to the BG pediatric primary care location. Depending on the amount of
patients on the list, we will attempt to make at least one initial call per eligible patient to remind
them that they are due for an HPV (and any other) vaccination and offer to schedule them for a
care team visit (nurses only) or a physical exam, depending on which visit is most appropriate.
Prior to initiating the call, we will review each patient’s immunization report, check their last
appointment visit, check their last physical exam, and check for any scheduled or upcoming
appointments. We will use demographic information (telephone numbers) that are already
entered in the patient’s electronic record. Although some studies in the literature review
attempted to call and remind the patient directly, our project will only reach out to the
parent/guardian listed on the patient’s chart.
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If we are not able to obtain a copy of the list of eligible patients for the HPV vaccine,
then we will have to look for them manually on EPIC, the electronic health record. We will
search for patients based on their birthdates, starting with those born between and 7/9/2005 and
7/9/2007. This search should retrieve patients who are between 11- and 13-years-old, which has
been the target population of previous HPV improvement efforts. After the initial search based
on birthdate, we should be able to create a list of patients who belong to the BG primary care
clinic, based on the primary care provider listed on their chart. This method would be a last
resort, but would still be effective if needed.
If a parent declines to schedule for an HPV (or other) vaccine, the patient will be placed
on a list for follow up, but will no longer receive calls. If a parent does not answer, we will leave
a scripted message on their voice mail if possible. If a parent does not answer, and we are not
able to leave a message, we will attempt to call the parent again on another day. If we do not
have an updated phone number for the patient (the phone number is not active or we are
informed we have the incorrect phone number), we will follow up with a letter sent to the
address on file. If a parent answers and agrees to schedule a visit, an appointment will be secured
at that time and a future order for necessary vaccines will either be pended to the RN by the
medical assistant, or ordered and signed by the RN. If a PSR secures the appointment, they will
send a request for orders for the vaccines to the care team.
Measures
According to a video from the Institute for Healthcare Improvement (IHI) (2018), which
discusses the family of measures, the two most important measures are outcome and process
measures. Outcome measures reflect the impact of the health care intervention or strategy on the
health status of patients (Agency for Healthcare Research and Quality, 2015). For this project,
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outcome measures would include the HPV vaccination initiation and completion rates, and
number of HPV vaccines given per day, week, and duration of the project. Process measures are
what a healthcare provider does to maintain or improve health (AHRQ, 2015). For this project,
process measures would include the number of phone calls made, number of letters sent, and
number of appointments scheduled as a result of the outreach and reminder/recall efforts.
According to the “4 Pillars Program”, it can be useful to track the “used opportunities to
vaccinate”, which can be calculated by dividing the number of people vaccinated by the number
of persons seen (University of Pittsburg, 2018). Additionally, the number of “simultaneous
immunizations” given can also be useful, and that is calculated by the number of persons given
two or more vaccines during the same visit divided by the number of persons given at least one
vaccine (University of Pittsburg, 2018). Both of these would examples of an outcome measure,
but they could also be seen as balancing measures (See Appendix I).
Ethical Considerations
Two of the major ethical considerations of this project include patient privacy and
autonomy. The HPV vaccine is one of the few vaccines that does not require parental consent for
it to be administered to a patient under the age of 18. In 2011, California law AB 499 or Chapter
652 gave minors, 12- to 17-years-old, the authority to consent to medical services that provide
prevention of sexually transmitted diseases (Hepatitis B, HPV, and HIV) without their parent’s
consent (California Immunization Coalition, 2013). If a patient is in the clinic and requests an
HPV vaccine without their parent’s consent, we do our best to maintain our patient’s privacy and
accommodate their request. Similarly, if a patient calls to make an appointment for an HPV
vaccine and wishes to keep it private from their parent’s, we will work with the patient to protect
their privacy and respect their right to make the choice for themselves.
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These issues become a little more complicated and can be tricky when calling parents to
remind them about their child’s overdue HPV vaccinations. For example, if a patient received
their first HPV vaccine without the knowledge or consent of the parent, and we call the parent to
remind them that the patient is due for their second dose, this could create a potential breach of
patient privacy, as well as conflict between the parent and the clinic or the parent and the patient.
We were unable to find any recommendations in the literature review to mitigate these
confidentiality issues, which was surprising because it would be expected for similar issues to
arise in other clinics and with other improvement projects. However, one of our lead physicians
suggested looking up the previous consent for the HPV vaccine (which is usually available and
scanned into the patient’s chart) to confirm who signed for the last vaccine consent.
Results
The pediatric primary care clinic started planning for the project on May 21, 2018,
however, implementation of the first PDSA cycle of the project was expected to start July 9,
2018. Due to a delay in access to the eligible patient list, we were unable to start the outreach
calls until July 13, 2018. The first PDSA cycle of the project was expected to run for three
weeks, finalizing by July 30, 2018; however, the last day of outreach calls was July 27, 2018.
Final data measurement for this PDSA cycle was also to be completed by July 30, 2018. Please
refer to timeline for more detailed explanation of the project’s progress (See Appendix I) and
PDSA cycle for more information (See Appendix Q).
According to the most recent data report, there were 545 eligible patients in April of
2018. Our initial plan was to call all of these patients at least once. However, we did not expect
that the outreach calls would take as long as they did. Some calls took between 5-10 minutes,
which included a chart review to check on their HPV status, and if they were due for any other
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vaccines or physical exam. Also, for every patient that had already initiated the HPV series, we
had to check if the prior consent had been signed by the parent or the patient to avoid a breach in
patient confidentiality. On the other hand, some calls took as long as 25-30 minutes, because
parents wanted us to check to see if their other children were due for vaccines or a physical exam
as well. Although the additional time spent helping parents with non-HPV appointments did not
benefit the project, it did benefit our overall patient care and improved access. Unfortunately, we
were only able to make 78 patient calls, which translates to 14% of our initial outreach goal.
Initially we also planned to follow up patient calls with mailed letters or electronic
messages through the patient portal. However, because the outreach calls were so time
consuming we were unable to send out any letters or messages. At the end of the project, we
decided that this would be a good strategy for a second PDSA cycle if the project was allowed to
continue. There were some initial concerns for patient privacy regarding mailed reminder letters,
consequently it would be important to have a team meeting to discuss and mitigate these
potential issues if we did move forward to the next PDSA cycle.
During the project we tracked a lot of different measures and outcomes. Some of the data
was obtained through chart reviews, which were also more time consuming than expected. The
rest of the data was obtained by keeping a log of patient calls and the outcomes of those calls
(See Appendix J). The data gathering process would have been more time- and cost-effective if
there was a way to automate the process through a report of some kind. Although we discussed
the possibility of connecting with an EHR specialist to help the process, we were unable to do so
during the time of project implementation. However, if the project is expected to continue, doing
so would streamline the process and make it much easier to keep track of some of the measures.
Additionally, learning how to run these reports and having access to them would free up more
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time for outreach calls and would enable the team to reach out to more patients, increasing the
benefits of the project.
One of the main outcomes that we tracked was the “number of HPV vaccines given” (See
Appendix K). There seem to be less points below the median after the HPV outreach calls were
implemented, but it is hard to tell because there is not as much data as in the baseline. We
tracked “missed opportunities for vaccination” (See Appendix L). After project implementation
the points above the median are not as high, and more points seem lower than during the baseline
data; suggesting a decrease in this measure. However, it is possible that this measure decreased
simply because it is “back to school season”, where there is an increased number of patients
being seen for physicals and school-mandated vaccines, instead of the benefit being related to the
efforts of the quality improvement project. We thought it would be interesting to track “missed
opportunities for vaccination” specifically to HPV since this was the main focus of the project
(See Appendix M). Again, there seem to be more points below the median after project
implementation, except for the two high points towards the end of the data. One possible
explanation for the increase in missed opportunities for HPV could be related to the new
adolescent vaccine workflow that I described previously; mainly the first HPV now being
recommended at 10 years old. Conversely, it could also be related to the office seeing more
patients for physicals and families requesting to have only vaccines that necessary for school
registration and entry. “Used opportunities to vaccinate” (See Appendix N) and “simultaneous
vaccines given” (See Appendix O) were also tracked as balancing measures. Although there was
no increase in either measure as a result of the project, there does seem to be less points below
the median baseline in both data sets.
Summary
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As a result of the project, we attempted to call 78 patients and we were able to reach 69
patients total. We were unable to reach nine of those patients due to them moving, switching
providers, or not having updated contact number on their patient information section of the chart.
Out of the 69 patients reached, we left 37 messages and scheduled 25 initial appointments for
either a physical exam or a nurse-only (injection-only) visit. Three patients outright refused the
HPV vaccine and four patients gave an excuse to avoid scheduling an appointment during the
outreach call. A second review of the data was completed about two weeks after the end of the
outreach calls, and we discovered that an additional 15 appointments were scheduled as a result
of the messages that were left, for a total of 40 appointments scheduled. Out of the patients who
came in for their appointments, 11 patients completed the HPV series and two patients initiated
the HPV series; this led to an improvement of about 2%, which was less than our goal of 5-10%
improvement. However, because of the appointments scheduled were future appointments, we
were unable to collect a significant portion of the data. If all 40 patients who were scheduled as a
result of the outreach calls came in to their appointments and received an HPV vaccine, then that
would translate to an improvement rate of 7% which would meet our goal.
We suspect that the “back to school” season was helpful to increase the amount of patients
who were willing to come in for a visit. About half of the patients scheduled were also due for a
physical exam and this seemed to help motivate the families to come in because they also needed
to have school forms filled out by the physician. Interestingly, a review of the appointment data
illustrates that the appointment types were evenly split in half, 20 patients were scheduled for a
physical exam, and 20 patients were scheduled for a nurses visit.
Conclusion
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Based on our results of this short test of change, we concluded that outreach calls were
helpful to improve the HPV initiation and completion rates at the BG clinic. Although the initial
improvement rates did not meet our improvement goal, there is definitely potential for the
strategy if it is adopted on a more long-term basis. Our findings were somewhat consistent with
the results of the literature review, since we did experience some improvement in our HPV rates.
The literature review did warn that the benefits of outreach calls are not sustainable, however it
is hard to say if this is true for our clinic. It would be important to test this strategy for a longer
and more consistent basis to determine whether this is accurate. On the other hand, it would be
important to make some changes to the process of the outreach calls to ensure that it is
sustainable.
Initially, we thought that a clinical person, such as the CNL, would be in the perfect
position to execute the outreach calls due to their increased knowledge of the HPV disease and
vaccine. As a clinician and educator, the CNL is in the best position to address many of the
common reasons for HPV vaccine refusal. However, during the process of the outreach calls, it
became evident that most people were already decided one way or the other. Those who opposed
the HPV vaccine, did so strongly and did not really want to discuss their decision. Those who
agreed to the HPV vaccine were appreciative of the reminder calls and were willing to schedule
an appointment; in this case, it was more a matter of convenience or access and availability.
Consequently, in order to sustain this type of outreach it would be important to recruit other (less
costly?) staff members in order for the project to be more cost-effective. Since now we also
know that the outreach calls can take a long time to complete, it would be necessary to have
dedicated time for this outreach that does not take time away from direct patient care and other
day-to-day responsibilities.
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As previously discussed, PSRs were already been doing outreach calls as part of the
initial HPV Improvement Project that was started in 2017. This group of staff was in charge of
outreach calls for 17 different pediatric clinics and did not have a knowledge or familiarity with
the nuances of each clinic and patient population. The previous attempt at outreach calls were
also not very consistent, and it was unclear when the outreach calls had stopped or if they were
still ongoing. Therefore, if the BG clinic is able to embrace and sustain the project as part of the
daily clinic responsibilities and we can show that the strategy is effective in increasing our HPV
rates, we could then attempt to spread the project to the other three pediatric clinics in the
division, and ultimately to the other 13 clinics in the organization.
It is evident that there is still much work to be done in order to increase the rates of HPV
vaccine initiation and completion to meet the recommendations and guidelines of national
experts; this is true for our clinic as well as for other clinics across the state and across country.
Outreach and reminder calls are just one strategy that has shown to be of benefit, however, it is
important to consider and research other strategies as well. Thankfully, there is a significant
amount of research and evidence-based recommendations to improve HPV and other vaccine
uptake in the primary care setting. However, it is important for the clinic and staff to be proactive
and search out this information to improve the outcomes of our patients by providing them with
the best preventative care possible. As healthcare continues to move away from just treating
illness and disease, and becomes more focused on prevention, preventative measures such as
vaccines will become more even more important to track as they have been proven to increase a
patient’s quality of life and improve their outcome in the long-term.
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relevance)

Brigham, K. S, Woods,
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Sandora, T. J., & Blood,
E. A. (2015).
Randomized controlled
trial of an immunization
recall intervention for
adolescents. Pediatrics,
130(3), 507-514. DOI:
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RCT

-13-17 year
olds at
Adolescent
Medicine
Practice at
Boston’s
Children’s
Hospital
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least 1 of 3 IZs
(MCV4, Tdap,
Varicella).
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physical within
3 years
-1099 patients
identified, 424
met inclusion
criteria

3 groups
-Control group (no
treatment) (1)
-Telephone calls to
the parent/guardian
(Parent Only) (2)
-Telephone calls to
the parent/guardian
and the adolescent
(Parent/Adol) (3)

-Intention to treat
analysis:
improved IZ rates at 4
weeks for both
intervention arms:
1. 7.1%
2. 14.4%
3. 14.5% (P=.09)
-unadjusted odds of
receiving 1 or more
vaccines during 4-week
follow-up period were:
2. 2.20 x higher (95% CI
0.99-4.89)
3. 2.22 x higher (95% CI
1.00-4.94)
-adjusted odds
(stratification and
demographic factors)
2. nonsignificant OR 2.02,
95% CI 0.89-4.56
3. OR 2.27 95% CI 1.005.18
-As-Treated Analysis:
2. 79 (56.4%) of
parents/guardians were
successfully reached
3. 70 (50.7%) of the
parents/guardians and 30
(21.7%) adolescents were
successfully reached
-Post Hoc Analysis: 4
weeks after actual
intervention, showed:
significant increased rate
of IZ when
2. 24.4% parent alone was
reached
3. 20.1% parent and
adolescent both reached
1. 5.6% with no contact
-Multivariate analysis:
2. OR 5.31 (95% CI 2.6610.63
3. OR 4.72 (95% CI 1.6213.79)
Other:
Age was also an
independent predictor of
receiving an
immunization, with older
adolescents being less
likely to receive an
immunization
-Post Hoc Analysis: 1 year
after actual intervention
showed:
1. 30.0% no contact
(P<.001)
2. significant increased
rate of IZ (51.3%)

Strengths:
-Showed improvement
in vaccination rates in
the short term
- Shows the importance
of clinics maintaining
UTD contact
information for
patients/parents
Weaknesses:
-Did not show
improvement over the
long term
-Difficult to reach
parents/patients by
phone
-Study performed in one
location only, may not
be generalizable
Relevance:
-HPV vaccine was not
included in the RCT
- Study was aimed at
adolescent vaccines
-Were not able to reach
after 4 telephone calls,
important to examine
other methods: email,
texting, social media,
school-based outreach
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3. significant increased
rate of IZ (63.3%)
In multivariate analysis:
2. OR 2.40 (95% CI 1.513.82)
3. OR 3.78 (95% CI 1.688.52)

Chao, C., Preciado, M.,
Slezak, J., & Lanfang,
X. (2014). A
randomized intervention
of reminder letter for
Human Papillomavirus
vaccine series
completion. Journal of
Adolescent Health, 56,
85-90. Doi:
10.1016/j.jadohealth.
2014.08.014

Randomized
intervention
study

-Female
patients at
KPSC
- had received
at least 1 dose
(no more than
2 doses) or
HPV
-between 9-26
yo at time of
first HPV
-12,282
patients
identified,
12,255 were
randomized,
after
randomization
50 more
patients were
found
ineligible.
12,205 met the
inclusion
criteria

2 groups:
-Control group
received standard
of care (no
intervention) (20%
of participants)
-Intervention group
would receive a
reminder letter
quarterly for those
who had not
completed the HPV
series (80% of
participants)

-Primary outcome was the
% of females who
completed the HPV series
- 3-dose completion rate
was 56.4% at the end of
the 12 months for
intervention group
- compared to 46.6% in
the control group (p< .01)
-Effect of intervention
greater in patients who
received first dose at 9-17
yo (24% relative increase)
-compared to patients who
received first dose at 1826 yo (18% relative
increase)
-Patients who had only
received 1 dose HPV at
baseline, 40% in
intervention and 30% in
control group completed
the HPV series
- 20% of girls and 43% f
young women who had
only received 1 dose of
HPV at baseline, did not
receive any more doses of
HPV during the
intervention period
-When examined each
race/ethnicity subgroup,
increase in completion
rates were highest in
blacks (14.3% absolute
difference), followed by
Hispanics (11.0%), and
Asian/Pacific Islanders
(9.9%) compared to
whites (7.7%).

Strengths:
-Reminder letter sent
quarterly was effective
intervention to increase
HPV completion rates
-Repeated reminders
over extended period
Weaknesses:
-Magnitude of
improvement was not
significant
-Comparison groups
were not of equal size
-Not all reminder letters
successfully delivered,
some returned as
undeliverable (388 or
4% of letters)
-Some participants
terminated membership
with KPSC and lost to
follow up (1,052 or
10% of intervention
group, and 332 or 14%
of control group.
-Completion rates did
not include HPV
vaccines
received/completed
outside of KPSC,
reported completion
rate might be at lower
limit
-Study did not
distinguish siblings,
having a sibling in
intervention group may
have affected patients in
control group
Relevance:
-HPV vaccine was
included in intervention
- Addresses/mitigates
racial/ethnic gaps in
HPV series completion
rates
-Other types of
interventions should be
explored
-More research is
needed to understanding
barriers

Suh, C. A, Saville, A.,
Daley, M. F., Glazner, J.
E., Barrow, J., Stockley,
… Kempe, A. (2012).
Effectiveness and net
cost of reminder/recall
for adolescent
immunizations.

RCT

-4 private
pediatric
practices, 400
adolescents in
each practice
-Aged 11-18
yo who have

2 groups
- Intervention
group (2 letters and
2 telephone calls)
*1 letter followed
up with auto dialer
telephone call, if
one month later

-Primary outcome was the
receipt of more than 1
targeted vaccine and
receipt of all targeted
vaccines with 6 months of
intervention
-Secondary outcome
included completion of

Strengths:
- Overall significant
increase in intervention
group for each vaccine.
R/R increased
immunization rates in 3
or 4 pediatric practices.
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Pediatrics, 129(6),
e1437-1445. Doi:
10.1542/peds.
2011-1714

Szilagyi, P. G., Schaffer,
S., Barth, R., Shone, L.
P., Humiston, S. G.,
Ambrose, S., &
Averhoff, F. (2006).
Effect of telephone
reminder/recall on
adolescent
immunizations and
preventive visits:
Results from a
randomized clinical
trial. Archives of
Pediatric & Adolescent
Medicine, 160(2), 157163. Doi:
10.1001/archpedi.

RCT

been seen in
the last 2 years
-who had not
received 1 or
more of
vaccines (tdap,
mcv4, or first
HPV for
female
patients).
-800
adolescents to
each group

patient still needed
immunization
another telephone
call would be done.
If one month later
patient still needed
immunizations,
final letter would
be sent.

-Adolescents
11-14 yo
- 4 urban
primary care
practices in
Rochester:
including 2
pediatric group
practices,
hospital based
pediatric clinic,
and family
medicine based
neighborhood
health center.

2 groups
-Study group. Was
sent audiotaped
telephone
reminders about a
scheduled or
needed
immunization or
physical exam.
Called weekly if no
response.
-Control group
received standard
care.

- Control group
(usual care), did not
include
reminder/recall
(R/R)

39
vaccine series at 12
months after intervention
(Hep A, Hep B, Varicella
and HPV- females only)
-751 (94%) of patients in
intervention group
received 1 recall phone
call and 1 recall letter, 34
(4%) received recall letters
only, 13 (2%) received at
least 1 recall call only, and
2 (<1%) received neither
recall calls or letters
-For 91 (11%) of patients,
recalls were stopped per
parent request
-A significantly higher
percentage of adolescents
in intervention group
received at least 1 targeted
vaccine (p<.001).
-In 3 practices the
intervention group had a
significant higher
proportion of adolescents
who received at least 1
vaccine, in 1 practice there
was no effect observed
-Adjusted RR to receive at
least 1 vaccine was 1.36
(95% CI 1.21-1.54)
- Significant higher
percentage of adolescent
in intervention group
received all targeted
vaccines (P< .001)
-In 3 practices
significantly higher
proportions of adolescents
in intervention group
received all targeted
vaccines, in practice 2
there was no change
-Adjusted RR to receive
all targeted vaccines was
1.44 (95% CI 1.25-1.67).
-Overall significant
increase in intervention
group for each vaccine,
(HPV rates were lower
than other 2 vaccines)

-Also resulted in higher
UTD rates for other
vaccines, Hep A and
Varicella, and higher
rate of HPV completion
rate
- If patients sibling met
inclusion data also, only
1 adolescent in
household was chosen
to be in study. Sibling
would get the same
intervention, but data
not analyzed
-Cost analysis of
intervention showed
positive net additional
revenues for 3 practices,
but 1 practice had a
loss.
Weaknesses:
Overall significant
increase in intervention
group for each vaccine,
but HPV rates were
lower than other 2
vaccines
Relevance:
-HPV vaccine was
included in the RCT,
but only for females
-Cost benefit analysis
showed positive net
revenue for 3 of 4
practices, suggesting
intervention is cost
effective. Only study so
far that has taken cost
into account

-At the end of the
intervention (18 months),
study group had higher
Hep B coverage (3 doses),
(62.0% vs. 57.8%)
-Both study and control
groups increased rates of
Hep B and Td
vaccinations, but only
significant difference was
in Hep B
-Intervention was most
effective during the first
few months of the study,
but benefit did not persist

Strengths:
-Showed improvement
in vaccination rates for
Hep B and Td in the
short term, but only Hep
B was significant
improvement
- Shows the importance
of clinics maintaining
UTD contact
information for
patients/parents
Weaknesses:
-Did not show
improvement over the
long term
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Szilagyi, P. G.,
Humiston, S. G.,
Gallivan, S., Albertin,
C., Sandler, M., &
Blumkin, A. (2011).
Effectiveness of a
citywide patient
immunization navigator
program on improving
adolescent
immunizations and
preventive care visit
rates. Archives of
Pediatric & Adolescent
Medicine, 165(5),547553. Doi:
10.1001/archpediatrics.
2011.73

RCT

Szilagyi, P. G., Albertin,
C., Humiston, S. G.,
Rand, C. M., Schaffer,
S., Brill, H., … &
Stokley, S. (2013). A
randomized trial of the
effect of centralized
reminder/recall on
immunization and

RCT

-seen within
the last 24
month
-Due for annual
physical,
tetanus booster
or Hep B
vaccination
-5902 potential
subjects, 3006
were eligible
for
randomization
-stratified into
2 equal age
groups (11-12
yo and 13-14
yo) then
randomly
assigned to
study or
control group
-Adolescents
11-15 yo
-8 primary care
practices in
Rochester,
including: 2
fed qualified
community
health centers,
2 pediatric
hospital-based
clinics, 1
family
medicine
teaching clinic,
1 hospitalassociated
medicinepediatrics
practice, and 2
urban private
practices.
-seen within
the last 2 years
-7547
adolescents
identified and
randomized

-adolescents
11-17 yo
-9369 total
adolescents
served by 37
practices
practices (22
pediatric, 13
family
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-Difficult to reach
parents/patients by
phone
-Older study
Relevance:
-HPV vaccine was not
included in the RCT,
not yet approved
- Lack of telephones,
incorrect telephone
numbers, changed
numbers common
among impoverished
families – multiple
telephone numbers vs. 1
(single) telephone
number represented less
mobile group and more
likely to receive
intervention

2 groups
-Intervention –
tiered protocol.
Delivered by
trained patient
immunization
navigator.
-Steps: patient
tracking,
reminders/recall
(telephone + mail),
home visits,
- Standard of care
control- all
practices routinely
sent
letter/telephone
reminders for
scheduled visits but
no active
reminder/recall
based on
vaccinations

-Primary outcome were
the immunization rates at
end of study
-Secondary outcome were
preventive care visit rates
during 12 months and the
costs
-Immunization rates at the
end of the study for all 3
vaccines combined
(including HPV for girls)
were 12-16% higher in
intervention group
compared to control
-Preventive care visit rates
were 9-17% higher in
intervention group
-Intervention had greater
effects on immunizations
for girls vs boys (26%
higher) and for black or
Hispanic than for whites
(40% and 27% higher).
-Intervention had greater
effect on preventive care
visits for those without
previous preventive care
visits (13% higher).
-71% intervention group
received telephone/mail
reminders, 12% home visit

Strengths:
-Large scale study,
included more than 40%
adolescents in
Rochester
-Broad spectrum of
primary care practices
- Cost effective: $3.81
per adolescent per
month
-Benefit of tiered
intervention. More
intense intervention
reserved for patients
who do not respond to
lower-level
interventions
Weaknesses:
-Inability to distinguish
impact of different parts
of tiered intervention
-Since baseline IZ rates
were low, benefits of
intervention may not
persist as rates increase.
Relevance:
-HPV vaccine was
included in the RCT, for
females only
- Study was aimed at
adolescent vaccines
-Considered cost
-RN unable to make
house calls, new SW
could be a good
resource for
collaboration

3 groups
- intervention:
mailed letter. Sent
at 10-week
intervals for Tdap,
MCV4 and
preventive care
visits (Max 5

-Main outcome measure
were immunization rates
for routine vaccines
(MCV4, Tdap, HOV) and
preventive visit rates at
end of study
-Secondary outcome
measures were process
measures for mailed

Strengths:
-Only 56 (6%) of 1431
mailed reminders were
returned
- Siblings allocated to
the same group
Weaknesses:
-Managed care database
lacked telephone
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preventive care visits for
adolescents. Academic
Pediatrics, 13(3), 204213. Doi: 10.1016/j.acap
.2013.01.002

medicine, 2
internal
medicine).
-4,115 youths
identified from
37 primary care
-no preventive
care visit
within 14
months,
eligible for
Tdap, MCV4,
or HPV.

reminders in 12
months)
For 1st dose HPV
every 10 weeks,
and for 2nd and 3rd
dose every 5 weeks
(8 max reminders
per dose)
-intervention:
telephone
reminders. Sent at
same frequency as
letters.
-control (standard
care from each
practice, some
already used
telephone or mailed
reminders for
scheduled visits
and for those
behind on
vaccinations)
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reminders (returned
letters), and telephone
reminders (busy, no
answer, machine), and
those who opted out.
-Assessed missed
opportunities.
- Immunization rates for
individual vaccines and
for all vaccines combined
were 4-9% greater for
intervention group
compared to control
-22% of adolescents
missing a vaccine were
mailed a reminder, 17%
were telephoned
-13% of control group
received all vaccinations
by end of study
-Results of two
interventions were
significantly different
compared to control
-Overall immunization
rates were 56% for mailed
reminder group, 53% for
telephone reminders
group, and 50% for
controls group
-65% of mailed reminder
group, 63% of telephone
reminder group and 59%
of control group patients
had a preventative care
visit
-Preventive visits actually
declined in the control
group from 63% to 59%
-Fewer missed
opportunities in
intervention groups
compared to controls

number (41%) or a
“geocodable” address
(3.6%)
- 388 (27%) of
households in telephone
reminder group did not
answer or VM answered
-Challenge is still lack
of accurate contact
information- should
update contact
information at every
encounter
-Baseline
immunizations were
lower, benefits of
intervention decrease as
rates improve
Relevance:
-HPV vaccine was
included in the RCT
- Study was aimed at
adolescent vaccines
-Also included
preventive visits
-Centralized systems by
managed care
organizations- may not
be applicable to project
since it is too large
scale. Sutter/PAMF has
a centralized reminder
system, but not for
vaccine only
appointments(?)
-Modest cost: $18.78
per adolescent per year
for mailed reminders,
$16.68 per adolescent
per year for telephone
reminders
-ROI is difficult to
determine d/t multiple
benefits of added IZs +
preventive visits,
potentially accruing
over the years
-More intensive tiered
outreach have greater
impact, but more costly
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Appendix C
Pillars
1.Convenience
and Easy Access

2. Patient
Communication

3. Enhanced
Vaccination
Systems

4. Motivation

(University, 2018)

“4 Pillars Practice Transformation Program”
Strategies
• Use every patient visit type as an opportunity to vaccinate.
• Offer open access/walk-in vaccination during office hours.
• Promote simultaneous vaccination
• Hold express vaccination clinics outside normal office hours where only
vaccines are offered, with streamlined flow systems for check-in, screening,
and record keeping.
• Create a dedicated vaccination station.
• Extend the influenza vaccination season by vaccinating as soon as supplies
arrive and continuing to vaccinate as long as flu is circulating in the
community.
• Provide information about vaccine preventable diseases at the beginning of
every visit.
• Enroll patients in electronic health portal.
• Train staff to discuss vaccines during routine processes such as vital signs.
• Discuss the serious nature of vaccine preventable diseases.
• Promote 100% vaccination rates among staff to set a good example.
• Use on-hold messages, poster, fliers, electronic message board, website
posting, and social media to promote vaccination.
• Reach out by email, phone, text, mail, health portal etc. to recommend
vaccines that are due and about arrival of influenza vaccine supplies.
• Ensure sufficient vaccine inventory to handle increased immunizations.
• Assess vaccination eligibility for every patient encounter by a systematic
mechanism.
• Review accurate EMR vaccination record keeping.
• Update EMR with vaccinations as they are administered.
• Update EMR with vaccinations given elsewhere.
• Assess immunizations as part of vital signs.
• Establish standing order protocols for nursing and other patient care staff to
vaccinate without an individual physician order.
• Develop systematic process for vaccinating every person with a vaccination
need, such as standing orders or pending/queuing an order in the electronic
health record.
• Create a chart to track progress. Set an improvement goal and regularly track
progress (e.g., daily or weekly). Post the graph of your progress in a
prominent location and update it regularly.
• Provide ongoing feedback to staff on vaccination progress at staff meetings or
through other forms of communications.
• Create a competitive challenge for the most vaccinations given among your
staff.
• Provide rewards for successful results to create a fun-spirited environment.

IMPROVING RATES OF HPV VACCINATION
Appendix D

Lippit’s phases of change theory

(as cited in Mitchell, G., 2013)
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